📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Trifluoroibuprofen inhibits a-methylacyl coenzyme A racemase (AMACR/P504S), reduces cancer cell proliferation and inhibits in vivo tumor growth in aggressive prostate cancer models. (2014)

First Author: Festuccia C

Attributed to: Core Capability for Chemistry Research at the University of Liverpool funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.2174/1871520614666140327152607

PubMed Identifier: 24712326

Publication URI: http://europepmc.org/abstract/MED/24712326

Type: Journal Article/Review

Volume: 14

Parent Publication: Anti-cancer agents in medicinal chemistry

Issue: 7

ISSN: 1871-5206